News
Hosted on MSN1mon
Coherus divests Udenyca franchise to Intas for up to $558.4mCoherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback